Microfluidics
(OTCBB: MFLU), the exclusive global provider of Microfluidizer® high
shear fluid processors, and Particle Sciences Inc. (PSI) , an integrated provider
of drug development services, have expanded their partnership to include bottom-up
nanoparticle creation and continuous manufacturing via High-Shear Microfluidics
Reaction Technology™ (MRT).
“The pharmaceutical, chemical and energy industries continue to tell
us that implementing a viable solution for continuous manufacturing is a strategic
priority over the next few years,” said Bill Kober, Microfluidics Vice
President of Sales for the Americas. “With High-Shear MRT, we believe
we have developed a unique technology for crystallization and chemical reactions
that has the potential to revolutionize large-scale production of drugs and
chemicals worldwide. Due to our expanded collaboration with an innovative thought
leader such as Particle Sciences, more pharmaceutical companies will be able
to take advantage of the process consulting and product operation expertise
required to optimize the commercial reward.”
Scientists from PSI continue to work alongside research engineers in the Microfluidics
Technology Center on how to evaluate and establish process conditions for a
wide variety of applications including inhalable drug, parenteral oncology treatments
and photovoltaics.
“Leading pharmaceutical companies from around the world trust PSI to
help them develop formulations that improve bioavailability, stability, target
delivery and production scale efficiencies,” said Mark Mitchnick, CEO
at Particle Sciences. “By adding High-Shear MRT to our portfolio of capabilities,
we are better able to assist customers with aggressive nanomaterial goals and
continuous manufacturing platform requirements. We are excited to offer these
new possibilities as an integral part of our complete suite of solutions.”